Moderna, Inc. has rallied ~23%, but rated a Sell due to deteriorating fundamentals. Learn more about MRNA stock here.
CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA® (mRNA-1345), the Company’s ...
NWAhomepage on MSN
FDA approves expanded use of Moderna’s RSV shot, but uncertainty remains
The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to ...
NEXSPIKE is Moderna's third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and ...
Moderna on Tuesday said it expects to see between $8 billion and $15 billion in sales from its Covid, RSV, flu and other respiratory vaccines in 2027. The biotech company said it sees a corresponding ...
You recently posted a couple of articles about the respiratory syncytial virus (RSV) vaccine and the benefits versus the ...
The recommendation by the CHMP should now result in approval of Arexvy in the broader age range in February next year, and ...
Since that moment, Moderna has taken steps to pave the path to long-term growth -- from cutting costs to focusing on its vast ...
From COVID-19 to the seasonal flu and RSV, vaccinations for respiratory viruses are typically delivered via intramuscular injection, which generates antibodies in the bloodstream. But the first line ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback